We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Top Research Reports for UnitedHealth, Morgan Stanley & Anheuser-Busch
Read MoreHide Full Article
Tuesday, March 20, 2018
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth (UNH - Free Report) , Morgan Stanley (MS - Free Report) and Anheuser-Busch (BUD - Free Report) . These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
UnitedHealth’s shares have marginally underperformed the Zacks Medical Insurance industry in the last one year (up +34.2% vs. +34.5%). The Zacks analyst likes the company’s robust Government business and continued strong growth at Optum. Its international business and strong capital position that allows for business investment are other positives.
It has been witnessing an increase in membership over many years. The company raised its 2018 earnings guidance led by tax reform upside. The stock has seen the Zacks Consensus Estimate for current-year earnings being revised 15.4% upward over the last 90 days. Nevertheless, membership loss in its fee based commercial business and Brazilian business will pull down overall membership growth.
Shares of Morgan Stanley have outperformed the Zacks Investment Banking industry over the last three months (+7.7% vs. +6.1%), supported by the company’s impressive earnings surprise history. It surpassed the Zacks Consensus Estimate in each of the trailing four quarters.
The Zacks analyst likes the company’s efforts to lower balance sheet risk, strengthen wealth management operations along with its cost saving initiatives. Further, lower tax rates will aid profitability in the quarters ahead. However, persistent fall in net interest income (despite rising interest rates) remains a concern. Also, overall trading weakness is expected to hurt the company’s top line growth in the near-term.
Anheuser-Busch’s shares have underperformed the Zacks Alcoholic Beverages industry over the last three months, gaining +0.8% vs. an increase of +2.2%. However, both top and bottom line outpaced estimates and improved year over year in the fourth quarter. In fact, the quarter marked earnings beat after seven consecutive negative surprises while revenues surpassed estimates after two straight misses.
The Zacks analyst likes its robust brand portfolio and solid geographical reach. The company keeps introducing near beer alternatives along with no- and low-alcohol beers to resonate with changing demand. Further, SABMiller’s buyout has enhanced its position in the global beer market.
Though the company anticipates delivering strong top-line growth for 2018, backed by solid brands performance and robust commercial plans, it sees volatility in certain key markets. Moreover, it envisions a soft first quarter, owing to difficult comparisons, and phasing of marketing and sales initiatives.
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trendsand Earnings Previewreports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Top Research Reports for UnitedHealth, Morgan Stanley & Anheuser-Busch
Tuesday, March 20, 2018
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth (UNH - Free Report) , Morgan Stanley (MS - Free Report) and Anheuser-Busch (BUD - Free Report) . These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
UnitedHealth’s shares have marginally underperformed the Zacks Medical Insurance industry in the last one year (up +34.2% vs. +34.5%). The Zacks analyst likes the company’s robust Government business and continued strong growth at Optum. Its international business and strong capital position that allows for business investment are other positives.
It has been witnessing an increase in membership over many years. The company raised its 2018 earnings guidance led by tax reform upside. The stock has seen the Zacks Consensus Estimate for current-year earnings being revised 15.4% upward over the last 90 days. Nevertheless, membership loss in its fee based commercial business and Brazilian business will pull down overall membership growth.
(You can read the full research report on UnitedHealth here >>>).
Shares of Morgan Stanley have outperformed the Zacks Investment Banking industry over the last three months (+7.7% vs. +6.1%), supported by the company’s impressive earnings surprise history. It surpassed the Zacks Consensus Estimate in each of the trailing four quarters.
The Zacks analyst likes the company’s efforts to lower balance sheet risk, strengthen wealth management operations along with its cost saving initiatives. Further, lower tax rates will aid profitability in the quarters ahead. However, persistent fall in net interest income (despite rising interest rates) remains a concern. Also, overall trading weakness is expected to hurt the company’s top line growth in the near-term.
(You can read the full research report on Morgan Stanley here >>>).
Anheuser-Busch’s shares have underperformed the Zacks Alcoholic Beverages industry over the last three months, gaining +0.8% vs. an increase of +2.2%. However, both top and bottom line outpaced estimates and improved year over year in the fourth quarter. In fact, the quarter marked earnings beat after seven consecutive negative surprises while revenues surpassed estimates after two straight misses.
The Zacks analyst likes its robust brand portfolio and solid geographical reach. The company keeps introducing near beer alternatives along with no- and low-alcohol beers to resonate with changing demand. Further, SABMiller’s buyout has enhanced its position in the global beer market.
Though the company anticipates delivering strong top-line growth for 2018, backed by solid brands performance and robust commercial plans, it sees volatility in certain key markets. Moreover, it envisions a soft first quarter, owing to difficult comparisons, and phasing of marketing and sales initiatives.
(You can read the full research report on Anheuser-Busch here >>>).
Other noteworthy reports we are featuring today include Cigna (CI - Free Report) , MetLife (MET - Free Report) and Intuitive Surgical (ISRG - Free Report) .
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>
Mark Vickery
Senior Editor
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>